AACR taking applications for SU2C-Cancer Research UK Fellowship

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print

THE AMERICAN ASSOCIATION FOR CANCER RESEARCH is now accepting applications for the Stand Up To Cancer-Cancer Research U.K. Translational Research Fellowship, which will provide up to four grants for postdoctoral or clinical research fellows, each up to $315,000, over a four-year period.

This grant opportunity is provided by SU2C and Cancer Research U.K. and is the first joint research project resulting from the collaboration between the two groups announced in 2012.

The fellowship will provide four years of research support to early-career investigators in the U.S. and U.K. Research projects must be translational in nature and address critical problems in cancer with the potential to deliver benefit to patients.

The proposed work must be performed in two phases, one in the U.S. and one in the U.K. Each phase must be one to three years in length, and the total support period for this fellowship is a maximum of four years.

Project proposals are due by noon ET July 28, via proposalCENTRAL.

For general information on eligibility criteria, the application process, and other details about this grant, visit the AACR website.

YOU MAY BE INTERESTED IN

“I don’t know of a single grant that left my desk that was not approved and funded,” NCI Director Anthony G. Letai said on this episode of The Cancer Letter Podcast. https://open.spotify.com/episode/2PFYGwliBDYEbxBXFd9MtB?si=95DNBAy0QGSKBX31_uETEA This episode is available on Spotify, Apple Podcasts, and Youtube. Letai recapped his first year as NCI director in conversation with Paul Goldberg,...

A year ago, when he was sworn in as director of the National Cancer Institute, Anthony G. Letai set a goal: Reassure cancer researchers that the institute will keep a steady course aimed at finding treatments for cancer.
Michael R. Caputo, a cancer survivor and a Republican political operative with a wide-ranging resume, was named to the President’s Cancer Panel, a board formed under the National Cancer Act to monitor the National Cancer Program and report to the president about “barriers to progress in reducing the burden of cancer.”
For over two decades, the ASCO Genitourinary Cancers Symposiumhas stood as the premier global event that has helped advance cancer science and transform care. The 2027 Symposium will continue this legacy from Feb. 11–13 in San Francisco by bringing together the largest international audience in GU oncology to help define tomorrow’s standards of care. 

Never miss an issue!

Get alerts for our award-winning coverage in your inbox.

Login